Analytical Support for Drug Manufacturing in the United States - From Active Pharmaceutical Ingredient Synthesis to Drug Product Shelf Life

Drug Information Journal

Volumn 37, Issue 4, 2003, Pages 407-438

  Velagaleti, Ranga ^a   Burns, Philip K ^a   Gill, Michael ^a  

^a BASF Corporation   (United States)

Author keywords

Analytical; GMP; Manufacturing; Pharmaceuticals; Quality

Indexed keywords

DRUG; PHARMACEUTICAL INGREDIENT; UNCLASSIFIED DRUG;

ANALYTIC METHOD; CRYSTAL; DRUG APPROVAL; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PACKAGING; DRUG PURITY; DRUG QUALITY; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; EQUIPMENT; MEDICAL LITERATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SHELF LIFE; UNITED STATES;

EID: 0345689495     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150303700407     Document Type: Review

References (41)

1. Federal Food, Drug, and Cosmetic Act (Public Law No. 75-717 52 Stat. 1040) 1938.
2. International Conference on Harmonization. Guidance for Industry-Q7A: Good Manufacturing Practice (GMP) Guidance for Active Pharmaceutical Ingredients. Geneva, Switzerland: International Conference on Harmonization; August 2001.
3. US Food and Drug Administration. Current Good Manufacturing Practice for the Manufacture, Processing, Packaging and Holding of Drugs, 21 CFR-Parts 210 and 211. Rockville, MD: US Food and Drug Administration; March 1998.
4. US Food and Drug Administration. Drug Manufacturing Inspections-Compliance Program Guidance Manual. Rockville, MD: US Food and Drug Administration; October 2000.
5. DeCamp WH. The impact of polymorphism on drug development-A regulator's point of view. Am Pharm Rev. 2001;4(3):70-77.
6. The Pharmaceutical Codex. Principles and Practices of Pharmaceutics. London, UK: The Pharmaceutical Press; 1994.
7. Davidovich M, Mueller R, Raghavan K, Ranadive S, Vitez I, Sarsfield B, DiMarco J, Gougoutas J, Newman A. The role of X-ray diffraction as a powerful tool in characterization of various hydrants of a drug substance. Am Pharm Rev. 2001;4(1):53-60.
8. United States Pharmacopeial Convention, Inc. The United States Pharmacopeia (USP)/The National Formulary (NF). USP 25. NF 20. Rockville, MD: United States Pharmacopeial Convention, Inc.; January 2002.
9. International Conference on Harmonization. Q3A (R): Impurities in New Drug Substances. Geneva, Switzerland: International Conference on Harmonization; July 2000.
10. International Conference on Harmonization. Q3B (R): Impurities in New Drug Products. Geneva, Switzerland: International Conference on Harmonization; July 2000.
11. International Conference on Harmonization. Q3C: Impurities: Residual Solvents. Geneva, Switzerland: International Conference on Harmonization; December 1997.
12. International Conference on Harmonization. Q2A: Guidelines on Validation of Analytical Procedures: Definitions and Terminology. Geneva, Switzerland: International Conference on Harmonization; March 1995.
13. International Conference on Harmonization. Q2B: Guidelines on the Validation of Analytical Procedures: Methodology. Geneva, Switzerland: International Conference on Harmonization; May 1997.
14. International Conference on Harmonization. Q1A (R): Stability Testing of New Drug Substances and Products. Geneva, Switzerland: International Conference on Harmonization; April 2000.
15. International Conference on Harmonization. Q1B: Photostability Testing of New Drug Substances and Products. Geneva, Switzerland: International Conference on Harmonization; November 1996.
16. International Conference on Harmonization. Q1 C: Stability Testing of New Dosage Forms. Geneva, Switzerland: International Conference on Harmonization; May 1997
17. International Conference on Harmonization. Q1D: Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products. Geneva, Switzerland: International Conference on Harmonization; September 2000.
18. US Food and Drug Administration. Guidance for Industry-Stability Testing of Drug Substances and Drug Products. Rockville, MD: US Food and Drug Administration; June 1998.
19. US Food and Drug Administration. Guidance for Industry-Content and Format of Investigational New Drug Applications for Phase 1 Studies of Drugs, Including Well Characterized, Therapeutic, Biotechnology Derived Products. Rockville, MD: US Food and Drug Administration; November 1995.
20. US Food and Drug Administration. Guidance for Industry-INDs for Phase 2 and 3 Studies of Drugs, Including Well Characterized, Therapeutic, Biotechnology Derived Products, Chemistry, Manufacturing and Controls Content and Format. Rockville, MD: US Food and Drug Administration; February 1999.
21. 21 CFR Part 312. Investigational New Drug Application. Rockville, MD: US Food and Drug Administration; April 1994.
22. 21 CFR Part 314. Application for FDA Approval to Market a New Drug or an Antibiotic Drug. Rockville, MD: US Food and Drug Administration; April 1994.
23. US Food and Drug Administration. Guidance for Industry-Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on Biopharmaceutics Classification System. Rockville, MD: US Food and Drug Administration; August 2000.
24. International Conference on Harmonization. Q6A (R): Specifications: Test Procedures and Acceptance Criteria for New Drug Substance and New Drug Products: Chemical Substances. Geneva, Switzerland: International Conference on Harmonization; December 2000.
25. US Food and Drug Administration. Guidance for Industry-Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products - Chemistry, Manufacturing, and Controls Documentation. Rockville, MD: US Food and Drug Administration; July 2002.
26. US Food and Drug Administration. Guidance for Industry-Investigation of Out of Specification (OOS) Test Results for Pharmaceutical Production. Rockville, MD: US Food and Drug Administration; September 1998.
27. Gentry AE. Methodical evaluation of OOS results-a problem solving approach. Am Pharm Rev. 2001;4(4):78-81.
28. Velagaleti R, Halliday J, Noland P. Analytical Support for Pharmaceutical Manufacturing-Translating Regulations and Guidelines into Laboratory Operations. In: Pharmaceutical Packaging and Manufacturing Sourcer. London, UK: Samedan Ltd. Pharmaceutical Publishing; March 1999.
29. US Food and Drug Administration. Guidance for Industry-Immediate Release Solid Oral Dosage Forms, Scale-up, and Post-approval Changes: In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. Rockville, MD: US Food and Drug Administration; November 1995.
30. US Food and Drug Administration. Guidance for Industry-Nonsterile Semisolid Dosage Forms, Scale-up, and Post-approval Changes: In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. Rockville, MD: US Food and Drug Administration; May 1997
31. US Food and Drug Administration. Guidance for Industry-Changes to the Approved NDA or ANDA. Rockville, MD: US Food and Drug Administration; November 1999.
32. US Food and Drug Administration. Reviewer Guidance-Validation of Chromatographic Methods. Rockville, MD: US Food and Drug Administration; November 1994.
33. Health Protection Branch. Acceptable Methods. Drugs Directorate Guidelines. Ottawa, Canada: Health Protection Branch. Health and Welfare Canada; July 1992.
34. Banker U. Pharmaceutical Dissolution Testing. New York, NY: Marcel Dekker, Inc.; 1992.
35. Storey DE. The role of dissolution testing in the design of immediate release dosage forms. Drug Inf J. 1996;30:1039-1044.
36. US Food and Drug Administration. Guide to Inspections of Validation of Cleaning Processes. Rockville, MD: US Food and Drug Administration; May 1993.
37. US Food and Drug Administration. Guide to Inspections of Bulk Pharmaceutical Chemicals. Rockville, MD: Food and Drug Administration; May 1994.
38. Kirsch RB. Validation of analytical methods in pharmaceutical cleaning assessment and validation. Pharma Tech Supp. 1998;22:40-45.
39. US Food and Drug Administration. Guidance for Industry-Container Closure Systems for Packaging Human Drugs and Biologics, Chemistry, Manufacturing and Controls Documentation. Rockville, MD: US Food and Drug Administration; May 1999.
40. Electronic Records and Electronic Signatures.21 CFR PART 11. Final Rule. Federal Register. 1997;62:13430-13466.
41. US Food and Drug Administration. CDER News Along the Pike. Office of Pharmaceutical Sciences (OPS) Forms Advisory Group for Process Analytical Technologies. Rockville, MD: US Food and Drug Administration; July 24, 2002;8(2).